View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 1, 2021updated 12 Jul 2022 11:13am

Awareness high about telemedicine and remote patient monitoring in clinical trials: Poll

The pharmaceutical industry is witnessing an unprecedented increase in the adoption of digital technologies, particularly in conducting clinical trials, as a result of the movement restrictions imposed due to the COVID-19 pandemic.

Digitisation is not only helping in reducing barriers to participation in clinical trials, but also boosting participant experience.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Verdict has conducted a poll to assess the awareness levels of various digital technologies being used in clinical trials such as telemedicine, remote patient monitoring, and mobile applications.

Analysis of the poll responses shows that awareness is good about telemedicine, remote patient monitoring and mobile applications being used in clinical trials. While 28% are aware of telemedicine, 22% are aware of remote patient monitoring and 20% are aware of the use of mobile applications.

Awareness about wearable devices and digital biomarkers is relatively lower among the poll respondents, with 13% and 12% respectively being aware of them. Whereas other connected devices with biosensors being used in clinical trials is known to just 5% of the respondents.

People most aware about the use of telemedicine and remote patient monitoring in clinical trials

The analysis is based on 93 responses received from the readers of Clinical Trials Arena, a Verdict network site, between 08 February and 18 May 2021.

Digital technologies in clinical trials

Clinical trials serve as the basis for validating new products and drugs, but the development process is often time-consuming and expensive. Digital health technologies such as telemedicine and wearable health devices are enabling pharmaceutical companies to perform trials safely, efficiently and at a much lower cost by conducting them remotely instead of a hospital or university.

Digital health tools enable passive reporting of data, which requires minimal or no effort from the participants. It helps in reducing the number of patients visits, improving outcomes and increasing the number of patients being monitored as well as the availability of data. These tools also make patient participation easier by improving adherence.

The COVID-19 pandemic has increased people’s awareness around clinical trials aided by the continuous media coverage related to vaccine development. The existing interest should be capitalised by communicating regarding ongoing research programmes to encourage participation. The concerns related to the use of digital tools in clinical trials, such as privacy and security, also need to be addressed to improve trust among patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena